Kala Pharmaceuticals, Inc. is advancing innovative treatments for ocular diseases addressing significant needs in both front and back of the eye based on the company's proprietary Mucus Penetrating Particle (MPP) platform technology. Kala's topical ocular MPP formulations enhance penetration into ocular tissue by facilitating penetration through the mucus layer of tear film.
Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering.
For more information, please visit www.kalarx.com.
What do you think of this story?
Select one of the options below. Your feedback will help tell CNN producers what to do with this iReport. If you'd like, you can explain your choice in the comments below.
Be and editor! Choose an option below: